Abstract:able to induce cell death in gynecologic epithelial cancer cells.Interestingly, retrospective evidence suggests that those obese women concurrently using statins as treatment of hypercholesterolemia, during their cancer treatment experienced better survival than those non-users.In the present work we investigate the effects of statins in leptin-induced signaling, migration and invasiveness in epithelial ovarian cancer cells.Material and Methods: Upon mock or Simvastatin (1 uM for 24 h) preincubation, three human ovarian cancer cell lines (A2780, SKOV3, HEY) and primary tissue culture cells (established from advanced epithelial ovarian cancer) were incubated with leptin (100 ng/ml, for up to 24h).Under these conditions, MTS, matrigel invasion, and wound healing assays were conducted.Immunoblotting for key players in leptin signaling pathway (pSTAT3, pERK, pAKT, RhoA, pFAK) upon similar conditions, with or without adding specific inhibitors (anti-leptin receptor antibody, AG490, U0126, LY 294002, and Fasudil) were also carried out.Results: Leptin increases migration and invasiveness of ovarian cancer cells through leptin receptor-mediated activation of JAK/STAT3, PI3/AKT, and RhoA pathways, since anti-leptin receptor antibody, AG490, LY and fasudil, respectively, all significantly decrease leptin-mediated cell migration and invasion.Simvastatin pre-treatment significantly reduces leptin-induced cell migration and invasion of ovarian cancer cells.As observed with specific inhibitors, immunoblotting shows that Simvastatin pre-treatment decreases leptin-mediated activation of all key players involved in leptin signaling pathway and participating in migration and invasiveness of cancer cells.Discussion: Leptin-mediated effects in migration and invasiveness of cancer cells offer a possible explanation for the more aggressive behavior of ovarian cancer and the lower survival observed in obese patients.The inhibitory effect of statins in leptin-induced signaling (besides its dose-dependent apoptotic effect in ovarian cancer cells) justifies considering the inclusion of lipophilic statins in the design of future clinical trials.

811 Development of a Fast in Vitro Assay to Screen New Gene Aberrations Identified Through Genomic Analysis of Pancreatic Tumours As Possible Drivers of Early Carcinogenesis